The Full Wiki

More info on Tenocyclidine

Tenocyclidine: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Tenocyclidine
Systematic (IUPAC) name
1-(1-(2-Thienyl)cyclohexyl)piperidine
Identifiers
CAS number 21500-98-1
ATC code none
PubChem 62751
Chemical data
Formula C 15H23NS 
Mol. mass 249.416 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status Schedule I / Class A
Routes  ?

Tenocyclidine (TCP) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is similar in effects to phencyclidine (PCP) but is considerably more potent. TCP has slightly different binding properties to PCP, with more affinity for the NMDA receptors,[1] but less affinity for the sigma receptors.[2] Because of its high affinity for the PCP site of the NMDA receptor complex, the 3H radiolabelled form of TCP is widely used in research into NMDA receptors.

TCP acts primarily as an NMDA receptor antagonist which blocks the activity of the NMDA receptor, however its increased stimulant effects compared to PCP suggests it also has relatively greater activity as a dopamine reuptake inhibitor (DRI). Due to its similarity in effects to PCP, TCP was placed into the Schedule I list of illegal drugs in the 1970s, although it was only briefly abused in the 1970s and 1980s and is now little known.

See also

References

  1. ^ Stirling JM, Cross AJ, Green AR. The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7.
  2. ^ Javitt DC, Jotkowitz A, Sircar R, Zukin SR. Non-competitive regulation of phencyclidine/sigma-receptors by the N-methyl-D-aspartate receptor antagonist D-(-)-2-amino-5-phosphonovaleric acid. Neuroscience Letters. 1987 Jul 22;78(2):193-8.
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message